Substantial variability in community respiratory syncytial virus season timing

Mullins, James A.; LaMonte, Ashley C.; Bresee, Joseph S.; Anderson, Larry J.

doi:10.1097/01.inf.0000090921.21313.d3

Cited by 154 publications

(131 citation statements)

References 10 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…We speculate that the decrease in hospitalization rates observed in the registry may reflect year-to-year variability in RSV epidemiology across seasons and geographic regions. 28,29 Other potential sources of variation were changes in participating sites, physicians, and study populations, and disparity in hospital admission criteria and RSV testing practices over the four consecutive seasons. In the registry, the number of hospitalizations was not based on direct review of hospital discharge records, but rather on chart review in pediatricians' offices and ongoing contact with patient caretakers during the study period.…”

Section: Discussionmentioning

confidence: 99%

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

Frogel

Nerwen

Cohen³

et al. 2008

J Perinatol

103

108

View full text Add to dashboard Cite

Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.Study Design: Prospective observational registry enrolling those who received X1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.Result: Of 19 548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.Conclusion: Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

Frogel

Nerwen

Cohen³

et al. 2008

J Perinatol

103

108

View full text Add to dashboard Cite

show abstract

“…However, as in other studies, we determined that a smaller proportion of diagnostic tests were positive for HMPV compared with other respiratory pathogens. [18][19][20][21] The data analyzed were not robust enough to assess regional trends in HMPV circulation.…”

Section: Discussionmentioning

confidence: 99%

Human Metapneumovirus Circulation in the United States, 2008 to 2014

Haynes¹,

Fowlkes

Schneider³

et al. 2016

Pediatrics

View full text Add to dashboard Cite

show abstract

“…In Australia, about 100,000 infants are infected by RSV every winter. In temperate regions of Australia, the occurrence of annual winter epidemics has been well demonstrated (Mullins et al, 2003). The incidence peaks in July, with 55-77% of all cases occurring between July and September.…”

Section: Developed Countriesmentioning

confidence: 99%